Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Immune Checkpoint Inhibitor‐Associated MyocarditisThe oncologist (Dayton, Ohio), 2018-08, Vol.23 (8), p.879-886 [Peer Reviewed Journal]AlphaMed Press 2018 ;AlphaMed Press 2018. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2018-0130 ;PMID: 29802219Full text available |
2 |
Material Type: Article
|
![]() |
Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An UpdateThe oncologist (Dayton, Ohio), 2019-10, Vol.24 (10), p.e990-e1005 [Peer Reviewed Journal]AlphaMed Press 2019 ;AlphaMed Press 2019. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2018-0337 ;PMID: 31217342Full text available |
3 |
Material Type: Article
|
![]() |
CheckMate 141: 1‐Year Update and Subgroup Analysis of Nivolumab as First‐Line Therapy in Patients with Recurrent/Metastatic Head and Neck CancerThe oncologist (Dayton, Ohio), 2018-09, Vol.23 (9), p.1079-1082 [Peer Reviewed Journal]AlphaMed Press 2018 ;AlphaMed Press 2018. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2017-0674 ;PMID: 29866947Full text available |
4 |
Material Type: Article
|
![]() |
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release SyndromeThe oncologist (Dayton, Ohio), 2018-08, Vol.23 (8), p.943-947 [Peer Reviewed Journal]Published 2018. This article is a U.S. Government work and is in the public domain in the USA ;Published 2018. This article is a U.S. Government work and is in the public domain in the USA. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2018-0028 ;PMID: 29622697Full text available |
5 |
Material Type: Article
|
![]() |
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeThe oncologist (Dayton, Ohio), 2017-06, Vol.22 (6), p.627-630 [Peer Reviewed Journal]2017 AlphaMed Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2016-0390 ;PMID: 28576858Full text available |
6 |
Material Type: Article
|
![]() |
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint InhibitorsThe oncologist (Dayton, Ohio), 2023-09, Vol.28 (9), p.771-779 [Peer Reviewed Journal]The Author(s) 2023. Published by Oxford University Press. 2023 ;The Author(s) 2023. Published by Oxford University Press. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyad082 ;PMID: 37023721Full text available |
7 |
Material Type: Article
|
![]() |
Early and Late Recurrence of Hepatitis B Virus‐Associated Hepatocellular CarcinomaThe oncologist (Dayton, Ohio), 2020-10, Vol.25 (10), p.e1541-e1551 [Peer Reviewed Journal]AlphaMed Press 2020 ;AlphaMed Press 2020. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2019-0944 ;PMID: 32472951Full text available |
8 |
Material Type: Article
|
![]() |
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib StudyThe oncologist (Dayton, Ohio), 2020-05, Vol.25 (5), p.e808-e815 [Peer Reviewed Journal]AlphaMed Press 2019 ;AlphaMed Press 2019. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2019-0473 ;PMID: 31740568Full text available |
9 |
Material Type: Article
|
![]() |
Anti‐Hu‐Associated Autoimmune Limbic Encephalitis in a Patient with PD‐1 Inhibitor‐Responsive Myxoid ChondrosarcomaThe oncologist (Dayton, Ohio), 2018-01, Vol.23 (1), p.118-120 [Peer Reviewed Journal]AlphaMed Press 2017 ;AlphaMed Press 2017. ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2017-0344 ;PMID: 29158368Full text available |
10 |
Material Type: Article
|
![]() |
Frequency of HLA-A02:01 in the Brazilian population and its impact on uveal melanoma systemic treatmentThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae112 ;PMID: 38785402Full text available |
11 |
Material Type: Article
|
![]() |
Unleashing patient voices: empowering adverse event assessment with complete patient-reported outcomesThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae105 ;PMID: 38785396Full text available |
12 |
Material Type: Article
|
![]() |
High-value breast cancer care within resource limitationsThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae080 ;PMID: 38780115Full text available |
13 |
Material Type: Article
|
![]() |
Opioid metabolism and drug-drug interaction in cancerThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae094 ;PMID: 38780124Full text available |
14 |
Material Type: Article
|
![]() |
Adjuvant treatment strategy evolution and risk stratification for hormone receptor-positive, human epidermal growth factor receptor-2 negative early breast cancer in ChinaThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae095 ;PMID: 38780143Full text available |
15 |
Material Type: Article
|
![]() |
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective studyThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae104 ;PMID: 38775839Full text available |
16 |
Material Type: Article
|
![]() |
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysisThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae099 ;PMID: 38776552Full text available |
17 |
Material Type: Article
|
![]() |
A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancerThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae098 ;PMID: 38776551Full text available |
18 |
Material Type: Article
|
![]() |
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizerThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae101 ;PMID: 38767987Full text available |
19 |
Material Type: Article
|
![]() |
Endocrine therapy in advanced high-grade ovarian cancer: real-life data from a multicenter study and a review of the literatureThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae093 ;PMID: 38768082Full text available |
20 |
Material Type: Article
|
![]() |
Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapyThe oncologist (Dayton, Ohio), 2024-05 [Peer Reviewed Journal]The Author(s) 2024. Published by Oxford University Press. ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyae089 ;PMID: 38768122Full text available |